PXD-101 Inhibitor

Belinostat is an inhibitor of hydroxamic acid-type histone deacetylase (HDAC, IC50 of 27nM in HeLa cell extracts), and with antineoplastic activity.

Plumb J A, Finn P W, Williams R J, et al. Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101[J]. Molecular Cancer Therapeutics, 2003, 2(8):721-728.
Plumb J A, Finn P W, Williams R J, et al. Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101[J]. Molecular Cancer Therapeutics, 2003, 2(8):721-728.
Chia S, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017 Sep 5;8(1):435.
Chia S, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017 Sep 5;8(1):435.

Small volumes of PXD-101, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5759309 is an inhibitor targeting PXD-101.